Suchergebnisse - "Ito, Yoshinori"

PubPharm (57)

1

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer : an ad hoc analysis of the JBCRG-C06 Safari study

enthalten in: Japanese journal of clinical oncology | 2022

von Kawaguchi, H. | Yamamoto, Y. | Saji, S. | +20

2

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Cortés, J. | Kim, S. | Chung, W. | +122

CommentIn: Nat Rev Clin Oncol. 2022 May;19(5):283. - PMID 35361895

3

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer : The Phase III KAITLIN Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Krop, I. | Im, S. | Barrios, C. | +20

CommentIn: J Clin Oncol. 2022 Jun 20;40(18):2066-2067. - PMID 35420886

4

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

enthalten in: Breast cancer research and treatment | 2021

von Fukada, I. | Ito, Y. | Kondo, N. | +17

5

Japanese subpopulation analysis of MONARCH 2 : phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

enthalten in: Breast cancer (Tokyo, Japan) | 2021

von Inoue, K. | Masuda, N. | Iwata, H. | +13

6

Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer

enthalten in: Virchows Archiv : an international journal of pathology | 2021

von Horii, R. | Nitta, H. | Nojima, M. | +7

7

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer : the COMACHI study

enthalten in: Breast cancer research and treatment | 2021

von Takahashi, M. | Ohtani, S. | Nagai, S. | +14

8

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer : a multicentre, open-label, randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Toi, M. | Imoto, S. | Ishida, T. | +22

ErratumIn: Lancet Oncol. 2022 Oct;23(10):e446. - PMID 36174627

9

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data : a follow-up analysis of the JBCRG-C06 Safari study

enthalten in: Breast cancer (Tokyo, Japan) | 2020

von Kawaguchi, H. | Masuda, N. | Nakayama, T. | +20

10

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer : study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

enthalten in: Trials | 2020

von Yamashita, T. | Masuda, N. | Saji, S. | +16

ErratumIn: Trials. 2020 Jun 8;21(1):503. - PMID 32513251

1
2
3
4
5
6
Nächster »
[6]